NCT03492775已完成2 期
Prospective Randomized Evaluation of Single Agent GA101 Versus GA101 Plus Bendamustine Followed by GA101
Prof. Dr. Wolfgang Hiddemann1 个研究点 分布在 1 个国家目标入组 46 人开始时间: 2017年12月12日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 46
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
The objective of this study is to test the efficacy and toxicity of a combined OBINUTUZUMAB/bendamustine therapy or single agent OBINUTUZUMAB in younger (< 60 years) medically non-fit, 'compromised' patients and in all older patients (≥ 60 years). For the assessment of the antilymphoma activity the overall response rate (ORR)" will be applied as primary endpoint.
Overall response is defined as complete or partial response after 19 - 21 weeks.
详细描述
Study design:
This is a randomized, open-label, multicenter phase II trial with a parallel-group design of two groups.
Randomization and Interventions:
Randomization between Obinutuzumab single agent treatment versus Obinutuzumab plus Bendamustine followed by Obinutuzumab
Treatment plans:
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Medically nonfit" patients < 60 years defined by
- •o ECOG > 2 or ECOG 0-2 with co-morbidities excluding intensive therapy according to local investigator's discretion
- •All patients ≥ 60 years in case of decision of investigator and patient to apply a reduced Treatment
- •Documentation of the CIRS-G, IADL, G8 and ECOG Scores before start of treatment
- •Histologically confirmed follicular lymphoma grade I, II or IIIa with material available for central pathology review
- •Stage III/IV or stage II without the option of curative radiotherapy
- •Age > 18 years
- •No prior therapy
- •Presence of at least one of the following symptoms or conditions requiring initiation of treatment:
- •Bulky disease according to the GELF criteria: nodal or extranodal mass > 7cm in its greater diameter
- •B symptoms (fever, drenching night sweats, or unintentional weight loss of >10% of normal body weight over a period of 6 months or less)
- •Hematopoietic insufficiency (at least one of the following: granulocytopenia <1500 cells/μl, Hb < 10 g/dl, thrombocytopenia <100.000 cells/μl)
- •Compressive syndrome
- •Pleural/peritoneal effusion
- •Symptomatic nodal or extranodal manifestations
- •At least one bi-dimensionally measurable lesion (> 1.5 cm in its largest dimension by CT scan or MRI)
- •Adequate hematologic function (unless abnormalities are related to NHL), defined as follows:
- •hemoglobin ≥ 9.0 g/dl
- •absolute neutrophil count ≥ 1500 /μL
- •platelet count ≥ 75000 /μl
- •Women who are not breast feeding, are using effective contraception, are not pregnant and agree not to become pregnant during participation in the trial and during the 18 months thereafter.
- •Men who agree not to father a child during participation in the trial and during the 18 months thereafter.
- •Written informed consent form
排除标准
- •"Medically fit" patients < 60 years with the option for more intensive induction therapy such as R-CHOP
- •Transformation to high-grade lymphoma (secondary to "low-grade" follicular lymphoma)
- •Grade IIIb follicular lymphoma
- •Presence or history of CNS disease (either CNS lymphoma or lymphomatous meningitis).
- •Regular use of corticosteroids during the last 4 weeks, unless administered at a dose equivalent to < 20 mg/day prednisone.
- •Prior (< 3 years) or concomitant malignancies except non-melanoma skin cancer or adequately treated in situ cervical cancer.
- •Major surgery (excluding lymph node biopsy) within 28 days prior to registration.
- •Necessity of rapid cytoreduction
- •Serious underlying medical conditions, which could impair the ability of the patient to tolerate the therapy offered in this trial (e.g. ongoing infection, uncontrolled diabetes mellitus, gastric ulcers, active autoimmune disease).
- •Severe hepatic impairment (serum bilirubin > 3.0 mg/dl)
- •Known sensitivity or allergy to murine products
- •Known hypersensitivity to any of the study drugs
- •Treatment within a clinical lymphoma trial within 30 days prior to trial entry
- •Positive test results for chronic HBV infection (defined as positive HBsAg serology) (mandatory testing) Patients with occult or prior HBV infection (defined as negative HBsAg and positive total HBcAb) may be included if HBV DNA is undetectable, provided that they are willing to undergo monthly DNA testing. Patients who have protective titers of hepatitis B surface antibody (HBSAb) after vaccination or prior but cured hepatitis B are eligible.
- •Positive test results for hepatitis C (mandatory hepatitis C virus [HCV] antibody serology testing). Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA
- •Known history of HIV seropositive status.
- •Patients with a history of confirmed PML
- •Vaccination with a live vaccine within 28 days prior to registration
- •Prior organ, bone marrow or peripheral blood stem cell transplantation
- •Any other co-existing medical or psychological condition that will preclude participation in the study or compromise the ability to understand its nature,meaning and implications
研究组 & 干预措施
Arm A:Obinutuzumab single agent
Active Comparator
Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1
If at least 'stable disease':
Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45
干预措施: Obinutuzumab (Drug)
Arm B:Obinutuzumab plus Bendamustine
Active Comparator
Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1 plus Bendamustine 70 mg/m2 iv d1+2 of each of four 28 -day cycles
If at least 'stable disease':
Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45
干预措施: Obinutuzumab (Drug)
Arm B:Obinutuzumab plus Bendamustine
Active Comparator
Obinutuzumab flat dose of 1000 mg on Day 1 of each of four 28 -day cycles and on Days 8 and 15 of Cycle 1 plus Bendamustine 70 mg/m2 iv d1+2 of each of four 28 -day cycles
If at least 'stable disease':
Obinutuzumab flat dose of 1000 mg at weeks 21, 29, 37 and 45
干预措施: Bendamustine (Drug)
结局指标
主要结局
ORR
时间窗: week 19 to 21
Overall response is defined as complete or partial response at the end of the initial treatment phase (after 19-21 weeks).
次要结局
- QoL(Through study completion, up to 5 years)
- Comorbidity assessment will be performed by using the G 8 (=geriatric) 8 screening score(Through study completion, up to 5 years)
- TTF(Through study completion, up to 5 years)
- CR(End of Induction of each patient, week 19 - 21)
- Frequency of Hospitalization(Through study completion, up to 3 years (per patient))
- Duration of Hospitalization(Through study completion, up to 3 years (per patient))
- Incidence of secondary transformation to aggressive lymphoma(Through study completion, up to 5 years)
- Comorbidity assessment will be performed by using the Instrumental Activities of Daily Living (=IADL)(Through study completion, up to 6.5 years)
- Event free survival, EFS(through study completion, up to 5 years)
- RD(week 19 up to 5,5 years follow up)
- Time to next anti-lymphoma treatment(Through study completion, up to 6.5 years)
- Number of SAEs(Through study completion, up to 5 years)
- Supportive Care(Through study completion, up to 5 years)
- Number of participants that had completed the therapy regularly (including: Total cumulative dose of obinutuzumab and bendamustine, number of cycles, duration of treatment)(Through study completion, up to 5 years)
- PFS(Through study completion, up to 5 years)
- Overall Survival(Through study completion, up to 5 years)
- Number of AEs(Through study completion, up to 5 years)
- Comorbidity assessment will be performed by using the Cumulative Illness Rating Scale for Geriatrics (CIRS-G)(Through study completion, up to 5 years)
研究者
Prof. Dr. Wolfgang Hiddemann
Prof. Dr. med. Wolfgang Hiddemann
Ludwig-Maximilians - University of Munich
研究点 (1)
Loading locations...
相似试验
招募中
2 期
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell LymphomaB Cell LymphomaNCT06415708Institute of Hematology & Blood Diseases Hospital, China134
招募中
2 期
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell LymphomaMantle Cell LymphomaNCT06504199Institute of Hematology & Blood Diseases Hospital, China39
终止
2 期
PR3-AAV Resilient Remission or PRRRANCA Associated VasculitisMicroscopic PolyangiitisGranulomatosis With PolyangiitisNCT05376319Mayo Clinic6
已完成
2 期
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) LymphomaMALT LYMPHOMANCT01015248Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea60
招募中
不适用
Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World StudyFollicular LymphomaNCT05846763Institute of Hematology & Blood Diseases Hospital, China50